♥️Meds for HCM very limited and don't prevent progression or reverse it
♥️HCM results from too many cross bridging and this drug prevents this
#EXPLORER #ESCCongress
Study & Characteristics &Results as below:
🔺251 Patients (largest trial in HCM)
🔺97% completed study
🔺Improved functional score and improved NYHA class
🔺⬇️post exercise gradients
🔺⬇️ resting and valsalva gradient
#ESCCongress
🔺Complete response in 27% as what is seen in septal myomectomy
🔺Very safe & well tolerated drug
🔺Question if beta blockers poorly tolerated in HCM & perhaps time to get rid of this as a med in HCM
📌75% of HCM patients saw a reduction in LVOT gradients
📌Need longterm data to know if effect on SCD & 56% had complete relief of symptoms
📌#Mavacamten very well tolerated & improved functional capacity
Is it time for this drug? Or need more data?